Oryzon Genomics - First vafidemstat efficacy data
In April 2019, Oryzon released the results from the first two cohorts in the Phase II REIMAGINE trial, namely borderline personality disorder (BPD) and attention deficit hyperactivity disorder (ADHD). The datasets included the first efficacy results, which demonstrated vafidemstat’s potential in aggression management in these patients. REIMAGINE is a basket trial, enrolling patients with two neurodegenerative and three psychiatric diseases, hence the cohorts were small (six patients each). All primary and secondary endpoints were met with high statistical significance, which prompted Oryzon to announce that it now plans to expand vafidemstat’s R&D beyond the currently ongoing other Phase II trials in Alzheimer’s disease (results in H219) and multiple sclerosis. Our valuation is higher at €430m or €11.0/share (€9.3/share previously) with the inclusion of BPD.Oryzon Genomics SA is a Spain-based biopharmaceutical company. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases. The Company's business model focuses on identifying biomarkers that can be translated in new therapeutic targets, as well as on investing in programs, mainly through the development of small molecules for two main indications: cancer and neurodegeneration. The Company develops investigational medicines till proof of concept (POC) phase and then partners the program with pharmaceutical entities, which are able to get the approval from drug agencies to bring these medicines to the patients. It cooperates with Roche. The Company is a subsidiary of Laboratorio Reig Jofre SA.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.